Search results
Author(s):
Miguel Mendes
Added:
3 years ago
As far as I know, the designation ‘optimal medical treatment’ was first used by the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial1 investigators as a synonym for the state-of-the-art measures encompassing drug regime, diet and physical activity recommended by the US guidelines for stable angina and acute coronary syndrome (ACS). Looking at the most…
View more
Author(s):
Antoni Bayés-Genís
Added:
3 years ago
The long-awaited 2016 European Society of Cardiology (ESC) guidelines for heart failure (HF)1 provide the large amount of novel research in HF since the previous guidelines published in 2012.2 Here, highlights of the 2016 guidelines are presented.
Definition of Heart Failure
The main terminology used to describe HF is historically based on measurement of the left ventricular ejection fraction …
View more
The ISCHEMIA Trial: Editorial
Author(s):
Pablo Avanzas
,
Juan Carlos Kaski
Added:
2 years ago
Article
Author(s):
Josep Gradolí
,
Verónica Vidal
,
Adrian JB Brady
,
et al
Added:
3 years ago
Atherosclerotic cardiovascular disease (CVD) comprises a large number of related pathologies, including ischaemic heart disease and peripheral arterial disease (PAD).1 This group of illnesses is the main cause of global morbidity and mortality and its prevalence increases remorselessly.2
Despite implementation of guideline-based therapy and optimal medical treatment, patients with established…
View more
Author(s):
HF Pitschner
,
P Reinesch
,
H Bahavar
,
et al
Added:
3 years ago
Since 1996 our electrophysiological diagnostic catheters and ablation catheters have been submitted to a certified (DIN EN ISO 13485) reprocessing company (Remed GmbH®, a member of the VANGUARD group). Each step of reprocessing that the catheters have to pass is certified according to the existing international regulations (standards, guidelines, etc.), which is required by law in Germany1,2 and…
View more
Author(s):
Patrycja Ganslmeier
,
Christof Schmid
Added:
3 years ago
End-stage heart failure is a leading cause of death of modern society. In the US almost five million people suffer from heart failure, with an annual incidence of 500,000 new cases. About 10% of the population beyond 70 years of age are affected (www.nhlbi.nih.gov). Estimations for Europe amount to 10 million and heart failure has overtaken cancer as the leading cause of death (www.destatis.de)…
View more
Author(s):
Markus Flesch
Added:
3 years ago
Introduction
Chronic heart failure (HF) is a common, malignant disease and is a major economic burden for healthcare systems in developed nations. It affects 5% to 10% of all people. In Germany, approximately 150,000 people are newly diagnosed with HF per year. Fifteen per cent of approximately 1.6 million HF patients in Germany are in advanced HF status, being classified as stage III-IV…
View more
Author(s):
Maurizio Gasparini
,
Alessio Cappelleri
,
Paola Galimberti
,
et al
Added:
3 years ago
Cardiac resynchronisation therapy (CRT) is an important device-based, non-pharmacological approach that has been shown to improve the outcome in selected patients with chronic heart failure (HF). Large randomised trials have clearly demonstrated that CRT improves left ventricular (LV) function and reduces both morbidity and mortality rates.1–5 Until a few years ago, CRT was indicated in patients…
View more
Author(s):
Leonardo Guimaraes
,
David del Val
,
Sebastien Bergeron
,
et al
Added:
3 years ago
Major advances in heart failure (HF) management have been achieved over the past three decades, yet it remains a syndrome with high morbidity and mortality, poor quality of life and high healthcare costs. Despite all advances in medical/device therapy, many HF patients continue to deteriorate, leading to poor quality of life and high rehospitalisation and mortality rates.1 The recent European…
View more
Author(s):
Khung Keong Yeo
,
Jack Wei Chieh Tan
,
David WM Muller
,
et al
Added:
2 years ago